GlobeNewswire Inc.··NaKyowa Kirin, Kura Oncology Launch Japanese Phase 2 Trial for FDA-Approved Ziftomenib
Kyowa Kirin and Kura Oncology begin Japanese Phase 2 registrational trial for ziftomenib in relapsed/refractory NPM1-mutated AML, following FDA approval.
KURAPhase 2 clinical trialhematologic malignancies